GUCA1B: A Potential Drug Target and Biomarker for glutamate decarboxylase-dependent mental disorders
GUCA1B: A Potential Drug Target and Biomarker for glutamate decarboxylase-dependent mental disorders
Mental disorders are a serious threat to human health, with the World Health Organization estimating that 250 million people worldwide are affected. Glutamic acid decarboxylase-dependent psychotic disorder (GAD-PD) is a subtype of schizophrenia characterized by symptoms of hallucinations and delusions that are often accompanied by the presence of other psychiatric disorders. Currently, treatments for GAD-PD are still limited and often lead to disease relapse. Therefore, finding new therapeutic targets is of high clinical significance.
GUCA1B is a protein that belongs to the glutamate decarboxylase family. GUCA1B plays an important biological role in organisms. It is a cofactor of glutamic acid decarboxylase (GAD). GAD is an important enzyme responsible for producing extracellular glutamate within cells, which is a necessary substance for maintaining brain function. However, GAD is also involved in the synthesis of many neurotransmitters, including the neurotoxin glutamate. When glutamate levels rise, GAD catalyzes the decarboxylation of glutamate to produce gamma-aminobutyric acid (GABA), a toxic neurotransmitter. GABA plays a key role in maintaining the stability and balance of the nervous system, but in patients with GAD-PD, GABA levels are often reduced, leading to dysfunction of the nervous system and ultimately psychiatric symptoms.
As a protein that regulates GAD function, GUCA1B has become an important target for studying the pathogenesis and therapeutic targets of GAD-PD. Studies have found that the expression level of GUCA1B is significantly reduced in GAD-PD patients, and its expression is significantly related to the severity and duration of the disease. In addition, the expression level of GUCA1B is also closely related to the severity of patients' psychiatric symptoms and disease prognosis. These results indicate that GUCA1B is important in the occurrence, development and treatment of GAD-PD.
Since the role of GUCA1B in GAD-PD is of important biological significance, studying it as a drug target has high clinical prospects. GUCA1B can serve as a potential drug target for the treatment of GAD-PD because intervention targeting GUCA1B can reduce glutamate levels in the nervous system, thereby improving patients' symptoms and prolonging the survival of patients with the disease.
In addition, GUCA1B can also be used as a biomarker to detect the severity and disease prognosis of GAD-PD. By detecting the expression level of GUCA1B, the severity of the patient's disease can be assessed and the survival period of the patient can be predicted. This biomarker has important clinical value in the diagnosis, treatment and prognostic assessment of GAD-PD.
In summary, GUCA1B, as a protein, has important research value in the pathogenesis and therapeutic target of GAD-PD. By targeting GUCA1B, the symptoms of GAD-PD patients can be improved and the survival of patients with the disease can be prolonged. At the same time, GUCA1B can also be used as a biomarker to detect the severity and disease prognosis of GAD-PD. Therefore, future research should target GUCA1B, deeply study the pathogenesis of GAD-PD, and explore new treatments and biomarkers to provide new ideas for improving the symptoms of GAD-PD patients and prolonging the survival of patients with the disease. .
Protein Name: Guanylate Cyclase Activator 1B
Functions: Stimulates two retinal guanylyl cyclases (GCs) GUCY2D and GUCY2F when free calcium ions concentration is low, and inhibits GUCY2D and GUCY2F when free calcium ions concentration is elevated (By similarity). This Ca(2+)-sensitive regulation of GCs is a key event in recovery of the dark state of rod photoreceptors following light exposure (By similarity). May be involved in cone photoreceptor response and recovery of response in bright light (By similarity)
The "GUCA1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GUCA1B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GUCA1C | GUCA2A | GUCA2B | GUCD1 | GUCY1A1 | GUCY1A2 | GUCY1B1 | GUCY1B2 | GUCY2C | GUCY2D | GUCY2EP | GUCY2F | GUCY2GP | GUF1 | GUK1 | GULOP | GULP1 | GUSB | GUSBP1 | GUSBP11 | GUSBP12 | GUSBP14 | GUSBP15 | GUSBP17 | GUSBP2 | GUSBP3 | GUSBP4 | GUSBP5 | GUSBP8 | GVINP1 | GVQW3 | GXYLT1 | GXYLT1P3 | GXYLT1P4 | GXYLT1P6 | GXYLT2 | GYG1 | GYG2 | GYPA | GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17
